RecruitingPhase 2NCT06104839

Safety and Efficacy of Oral NXC-736 in Adult Participants With Moderate and Severe Alopecia Areata

A Multi-center, Randomized, Double-blind, Placebo-controlled, Phase 2a Study to Evaluate the Efficacy and Safety of NXC736 in Patients With Moderate and Severe Alopecia Areata

Sponsor

NEXTGEN Bioscience

Enrollment

73 participants

Start Date

Sep 1, 2024

Study Type

INTERVENTIONAL

Conditions

Alopecia Areata

Summary

The purpose of this study is to evaluate the safety and efficacy of NXC-736 monotherapy in participants with severe alopecia areata (AA).

Eligibility

Min Age: 19 YearsMax Age: 65 Years

Inclusion Criteria5

Men or women between ≥19 and ≤65 years of age at the time of informed consent
Moderate and severe alopecia areata as assessed by a SALT score of 25% ≤ SALT < 95% at Screening and Day 1/Baseline
Current episode of hair loss for ≥6 months but <8 years
Stable disease condition (no significant growth of hair) in the last 6 months as assessed by the Investigator
Willing to keep the same hair style and color (eg, hair products, process, and timing for hair appointments) for the duration of the study

Exclusion Criteria4

Participants with the following medical history confirmed during screening:
ohter Types of alopecia other than alopecia areata (such as cicatricial/scarring alopecia \[including central centrifugal cicatricial alopecia\], traction alopecia, androgenic alopecia, telogen effluvium, etc.)
Active scalp inflammation, scalp infection, scalp psoriasis, or any other scalp condition that may interfere with the SALT assessment
Previous use of Janus kinase (JAK) inhibitor (oral or topical), including participation in clinical studies of JAK inhibitors

Interested in this trial?

Get notified about updates and connect with the research team.